n of 1 trial for an ornithine transcarbamylase deficiency carrier

Molecular Genetics and Metabolism

Volumn 94, Issue 2, 2008, Pages 157-161

  Hackett, A ^a,b   Gillard, J ^c   Wilcken, B ^d  

^a Hunter Genetics   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

l Arginine; n of 1 trial; Ornithine transcarbamylase enzyme deficiency; OTC; OTCD; Randomized controlled trial

Indexed keywords

ARGININE; GLUTAMINE; PLACEBO;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CARRIER; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; FEMALE; HUMAN; MOOD; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

AFFECT; ARGININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GENETIC DISEASES, X-LINKED; GLUTAMINE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; ORNITHINE CARBAMOYLTRANSFERASE; ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY DISEASE; QUALITY OF LIFE; QUESTIONNAIRES; X CHROMOSOME INACTIVATION;

EID: 43449102466     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.02.001     Document Type: Article

References (26)

1. Brusilow S., and Horwich A. In: Scriver C., Beaudet A., Sly W., and Valle D. (Eds). The Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York
2. Tuchman M., Morizono H., Rajagopal B., Plante R., and Allewell N. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J. Inherit. Metab. Dis. 21 (1998) S40-S58
3. Yamaguchi S., Brailey L.L., Morizono H., Bale A.E., and Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase OTC gene. Hum. Mutat. 27 (2006) 626-632
4. Finkelstein J.E., Hauser E.R., Leonard C.O., and Brusilow S.W. Late-onset ornithine transcarbamylase deficiency in male patients. J. Pediatr. 117 (1990) 897-902
5. Pridmore C., Clarke J., and Blaser S. Ornithine transcarbamylase deficiency in females: an often overlooked cause of treatable encephalopathy. J. Child Neurol. 10 (1995) 369-374
6. Batshaw M. Cerebral dysfunction in asymptomatic carriers of OTCD. NEJM 302 (1980) 482
7. Wraith J.E. Ornithine carbamoyltransferase deficiency. Arch. Dis. Child 84 (2001) 84-88
8. Feillet F., and Leonard J.V. Alternative pathway therapy for urea cycle disorders. J. Inherit. Metab. Dis. 21 (1998) 101-111
9. Brusilow S. Arginine an indispensable amino acid for patients with inborn errors of urea synthesis. J. Clin. Invest. 74 (1984) E2148
10. Maestri N., McGowan K., and Brusilow S. Plasma glutamine concentration: a guide to the management of urea cycle disorders. J. Pediatr. 121 (1992) E261
11. Guyatt G., Sackett D., Adachi J., Roberts R., Chong J., Rosenbloom D., and Keller J. A clinician's guide for conducting randomized trials in individual patients. Can. Med. Assoc. J. 139 (1988) 497-503
12. Bode-Boger S.M., Boger R.H., Galland A., Tsikas D., and Frolich J.C. l-Arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br. J. Clin. Pharmacol. 46 (1998) 489-497
13. Webster K., Cella D., and Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties applications, and interpretation. Health Qual. Life Outcomes 1 (2003) 79
14. Potter M., Hammond J., Sim K.-G., Green A., and Wilcken B. Ornithine carbamoyl transferase deficiency: improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes. J. Inherit. Metab. Dis. 24 (2001) 5-14
15. Ausems M.G., Bakker E., Berger R., Duran M., van Diggelen O.P., Keulemans J.L., de Valk H.W., Kneppers A.L., Dorland L., Eskes P.F., et al. Asymptomatic and late-onset ornithine transcarbamylase deficiency caused by a A208T mutation: clinical, biochemical and DNA analyses in a four-generation family. Am. J. Med. Genet. 68 (1997) 236-239
16. van Diggelen O.P., Zaremba J., He W., Keulemans J.L., Boer A.M., Reuser A.J., Ausems M.G., Smeitink J.A., Kowalczyk J., Pronicka E., et al. Asymptomatic and late-onset ornithine transcarbamylase (OTC) deficiency in males of a five-generation family, caused by an A208T mutation caused by an A208T mutation. Clin. Genet. 50 (1996) 310-316
17. Tuchman M., Morizono H., Reish O., Yuan X., and Allewell N.M. The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations. J. Med. Genet. 32 (1995) 680-688
18. Drogari E., and Leonard J. Late onset ornithine carbamoyl transferase deficiency in males. Arch. Dis. Child 63 (1988) 1363-1367
19. Gyato K., Wray J., Huang Z.J., Yudkoff M., and Batshaw M.L. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann. Neurol. 55 (2004) 80-86
20. Kawata A., Suda M., and Tanabe H. Adult-onset type II citrullinemia: clinical pictures before and after liver transplantation. Intern. Med. 36 (1997) 408-412
21. Takanashi J., Kurihara A., Tomita M., Kanazawa M., Yamamoto S., Morita F., Ikehira H., Tanada S., and Kohno Y. Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency. Neurology 59 (2002) 210-214
22. Takanashi J.-i., Barkovich A.J., Cheng S.F., Kostiner D., Baker J.C., and Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. AJNR Am. J. Neuroradiol. 24 (2003) 390-393
23. Maestri N.E., Brusilow S.W., Clissold D.B., and Bassett S.S. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335 (1996) 855-859
24. Maestri N.E., Lord C., Glynn M., Bale A., and Brusilow S.W. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine 77 (1998) 389-397
25. Guyatt G., Keller J., Jaeschke R., et al. The n of 1 randomized controlled trial: clinical usefulness. Ann. Intern. Med. 112 (1990) 293-299
26. Guyatt G.H., Juniper E.F., Walter S.D., Griffith L.E., and Goldstein R.S. Interpreting treatment effects in randomised trials. BMJ 316 (1998) 690-693